Extracorporeal treatment of acute liver failure

Colleen M. Brophy, Scott Nyberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acute liver failure (ALF) is a widespread problem with typically unfavorable prognosis. With the implementation of a liver support device in the clinical setting for treatment of patients with ALF, anticipated improvements include prolonging time available for spontaneous recovery and bridging to liver transplantation. Liver support could also serve to prevent systemic manifestations of ALF such as renal failure, pulmonary edema, systemic inflammatory response syndrome and cerebral edema evolving to brain death. Both non-cell based and cell based (bio-artificial) systems have been used in clinical trials. Systems with closed or open loop organization present different advantages and disadvantages; systems also differ in the membrane pore size for filtrate/dialysate exchange. Further optimization of liver assist devices is still required; when a system has proved to be successful in treating the debilitating results of ALF, the benefits will be enormous to liver failure patients.

Original languageEnglish (US)
JournalHepatology Research
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 31 2008

Fingerprint

Acute Liver Failure
Liver
Systemic Inflammatory Response Syndrome
Equipment and Supplies
Brain Death
Dialysis Solutions
Brain Edema
Liver Failure
Pulmonary Edema
Therapeutics
Liver Transplantation
Renal Insufficiency
Clinical Trials
Membranes

Keywords

  • Acute liver failure
  • Albumin dialysis
  • Bioartificial liver
  • Blood detoxification
  • Liver support device

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Extracorporeal treatment of acute liver failure. / Brophy, Colleen M.; Nyberg, Scott.

In: Hepatology Research, Vol. 38, No. SUPPL. 1, 31.12.2008.

Research output: Contribution to journalArticle

Brophy, Colleen M. ; Nyberg, Scott. / Extracorporeal treatment of acute liver failure. In: Hepatology Research. 2008 ; Vol. 38, No. SUPPL. 1.
@article{2f28d0f7b90a4fd281546a96c063f986,
title = "Extracorporeal treatment of acute liver failure",
abstract = "Acute liver failure (ALF) is a widespread problem with typically unfavorable prognosis. With the implementation of a liver support device in the clinical setting for treatment of patients with ALF, anticipated improvements include prolonging time available for spontaneous recovery and bridging to liver transplantation. Liver support could also serve to prevent systemic manifestations of ALF such as renal failure, pulmonary edema, systemic inflammatory response syndrome and cerebral edema evolving to brain death. Both non-cell based and cell based (bio-artificial) systems have been used in clinical trials. Systems with closed or open loop organization present different advantages and disadvantages; systems also differ in the membrane pore size for filtrate/dialysate exchange. Further optimization of liver assist devices is still required; when a system has proved to be successful in treating the debilitating results of ALF, the benefits will be enormous to liver failure patients.",
keywords = "Acute liver failure, Albumin dialysis, Bioartificial liver, Blood detoxification, Liver support device",
author = "Brophy, {Colleen M.} and Scott Nyberg",
year = "2008",
month = "12",
day = "31",
doi = "10.1111/j.1872-034X.2008.00424.x",
language = "English (US)",
volume = "38",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Extracorporeal treatment of acute liver failure

AU - Brophy, Colleen M.

AU - Nyberg, Scott

PY - 2008/12/31

Y1 - 2008/12/31

N2 - Acute liver failure (ALF) is a widespread problem with typically unfavorable prognosis. With the implementation of a liver support device in the clinical setting for treatment of patients with ALF, anticipated improvements include prolonging time available for spontaneous recovery and bridging to liver transplantation. Liver support could also serve to prevent systemic manifestations of ALF such as renal failure, pulmonary edema, systemic inflammatory response syndrome and cerebral edema evolving to brain death. Both non-cell based and cell based (bio-artificial) systems have been used in clinical trials. Systems with closed or open loop organization present different advantages and disadvantages; systems also differ in the membrane pore size for filtrate/dialysate exchange. Further optimization of liver assist devices is still required; when a system has proved to be successful in treating the debilitating results of ALF, the benefits will be enormous to liver failure patients.

AB - Acute liver failure (ALF) is a widespread problem with typically unfavorable prognosis. With the implementation of a liver support device in the clinical setting for treatment of patients with ALF, anticipated improvements include prolonging time available for spontaneous recovery and bridging to liver transplantation. Liver support could also serve to prevent systemic manifestations of ALF such as renal failure, pulmonary edema, systemic inflammatory response syndrome and cerebral edema evolving to brain death. Both non-cell based and cell based (bio-artificial) systems have been used in clinical trials. Systems with closed or open loop organization present different advantages and disadvantages; systems also differ in the membrane pore size for filtrate/dialysate exchange. Further optimization of liver assist devices is still required; when a system has proved to be successful in treating the debilitating results of ALF, the benefits will be enormous to liver failure patients.

KW - Acute liver failure

KW - Albumin dialysis

KW - Bioartificial liver

KW - Blood detoxification

KW - Liver support device

UR - http://www.scopus.com/inward/record.url?scp=58049090165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049090165&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2008.00424.x

DO - 10.1111/j.1872-034X.2008.00424.x

M3 - Article

C2 - 19125950

AN - SCOPUS:58049090165

VL - 38

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - SUPPL. 1

ER -